- Molecular NameFoscarnet
- SynonymN/A
- Weight122.981
- Drugbank_IDDB00529
- ACS_NO63585-09-1
- Show 3D model
- LogP (experiment)0.0
- LogP (predicted, AB/LogP v2.0)-2.63
- pka0.5, 3.4, 7.3
- LogD (pH=7, predicted)-7.78
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)0.9
- LogSw (predicted, AB/LogsW2.0)440.13
- Sw (mg/ml) (predicted, ACD/Labs)798.07
- No.of HBond Donors3
- No.of HBond Acceptors5
- No.of Rotatable Bonds1
- TPSA104.64
- StatusFDA approved
- AdministrationN/A
- PharmacologyThe conjugate base of the chemical compound with the formula HO2CPO3H2.
- Absorption_value18.0
- Absorption (description)Foscarnet is poorly absorbed after oral administration
- Caco_20.0
- Bioavailability9.0
- Protein binding15.5
- Volume of distribution (VD)0.35 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmNot metabolised to a great extent.
- Half life5.7 h
- ExcretionThe drug is excreted mostly unchanged in the urine by glomerular filtration and tubular secretion, and is also cleared by uptake into bones (14 to 22%). It is removed by haemodialysis.
- Urinary Excretion95
- Clerance1.6 ml/min/kg
- ToxicityRenal impairment is the major toxicity. Seizures related to alterations in plasma minerals and electrolytes have also been associated with foscarnet therapy.
- LD50 (rat)LD50> 2000 mg/kg
- LD50 (mouse)N/A